APO-VERAP SR TABLET (EXTENDED-RELEASE)

Riik: Kanada

keel: inglise

Allikas: Health Canada

Toimeaine:

VERAPAMIL HYDROCHLORIDE

Saadav alates:

APOTEX INC

ATC kood:

C08DA01

INN (Rahvusvaheline Nimetus):

VERAPAMIL

Annus:

240MG

Ravimvorm:

TABLET (EXTENDED-RELEASE)

Koostis:

VERAPAMIL HYDROCHLORIDE 240MG

Manustamisviis:

ORAL

Ühikuid pakis:

100

Retsepti tüüp:

Prescription

Terapeutiline ala:

MISCELLANEOUS CALCIUM-CHANNEL BLOCKING AGENTS

Toote kokkuvõte:

Active ingredient group (AIG) number: 0113846003; AHFS:

Volitamisolek:

APPROVED

Loa andmise kuupäev:

2003-02-20

Toote omadused

_Page 1 of 45 _
PRODUCT MONOGRAPH
PR
APO-VERAP SR
Verapamil Hydrochloride Sustained - Release Tablets
120 mg, 180 mg, and 240 mg
Apotex Standard
ANTIHYPERTENSIVE AGENT
APOTEX INC.
DATE OF REVISION:
150 SIGNET DRIVE
SEPTEMBER 3, 2020
TORONTO, ONTARIO
M9L 1T9
CONTROL NUMBER: 242524_ _
_Page 2 of 45 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
............................................................ 3
SUMMARY PRODUCT INFORMATION
........................................................................................
3
INDICATIONS AND CLINICAL USE
...............................................................................................
3
CONTRAINDICATIONS
....................................................................................................................
4
WARNINGS AND PRECAUTIONS
..................................................................................................
5
ADVERSE REACTIONS
...................................................................................................................
10
DRUG INTERACTIONS
...................................................................................................................
14
DOSAGE AND ADMINISTRATION
...............................................................................................
23
OVERDOSAGE
..................................................................................................................................
25
ACTION AND CLINICAL PHARMACOLOGY
.............................................................................
27
STORAGE AND STABILITY
...........................................................................................................
32
DOSAGE FORMS, COMPOSITION AND PACKAGING
............................................................. 32
PART II: SCIENTIFIC INFORMATION
....................................................................................
33
PHARMACEUTICAL INFORMATION
...........................................................................